Identification

Name
Pregabalin
Accession Number
DB00230  (APRD01198)
Type
Small Molecule
Groups
Approved, Illicit, Investigational
Description

Pregabalin is an anticonvulsant drug used for neuropathic pain, epilepsy and generalized anxiety disorder.[4] It presents antihyperalgesic actions by binding to the α2δ subunit of the voltage-dependent calcium channels without presenting antinociceptive actions.[5] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[13] It is considered to have a dependence liability if misused, and is classified as a Schedule V drug in the U.S.[4]

Structure
Thumb
Synonyms
  • (S)-3-(aminomethyl)-5-methylhexanoic acid
  • (S)-3-Isobutyl gaba
  • 3-Isobutyl gaba
  • CI 1008
  • S-(+)-3-isobutylgaba
External IDs
CI-1008
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-pregabalinCapsule300 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pregabalinCapsule75 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pregabalinCapsule150 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pregabalinCapsule50 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pregabalinCapsule225 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pregabalinCapsule100 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pregabalinCapsule25 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pregabalinCapsule200 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Act PregabalinCapsule225 mgOralActavis Pharma Company2013-03-06Not applicableCanada
Act PregabalinCapsule50 mgOralActavis Pharma Company2013-03-06Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pregabalinCapsule25 mgOralApotex Corporation2013-06-06Not applicableCanada
Apo-pregabalinCapsule300 mgOralApotex Corporation2013-04-22Not applicableCanada
Apo-pregabalinCapsule75 mgOralApotex Corporation2013-04-22Not applicableCanada
Apo-pregabalinCapsule225 mgOralApotex Corporation2013-05-09Not applicableCanada
Apo-pregabalinCapsule50 mgOralApotex Corporation2013-06-06Not applicableCanada
Apo-pregabalinCapsule150 mgOralApotex Corporation2013-04-22Not applicableCanada
Pregabalin AccordCapsule50 mgOralAccord Healthcare Limited2015-08-28Not applicableEu
Pregabalin AccordCapsule200 mgOralAccord Healthcare Limited2015-08-28Not applicableEu
Pregabalin AccordCapsule150 mgOralAccord Healthcare Limited2015-08-28Not applicableEu
Pregabalin AccordCapsule50 mgOralAccord Healthcare Limited2015-08-28Not applicableEu
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LyricaCapsule75 mg/1Oralbryant ranch prepack2004-12-30Not applicableUs
International/Other Brands
Lyrica (Pfizer) / Lyrica Cr (Pfizer)
Categories
UNII
55JG375S6M
CAS number
148553-50-8
Weight
Average: 159.2261
Monoisotopic: 159.125928793
Chemical Formula
C8H17NO2
InChI Key
AYXYPKUFHZROOJ-ZETCQYMHSA-N
InChI
InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1
IUPAC Name
(3S)-3-(aminomethyl)-5-methylhexanoic acid
SMILES
CC(C)C[[email protected]](CN)CC(O)=O

Pharmacology

Indication

Pregabalin is used for the management of neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, and postherpetic neuralgia. It is not approved for the management of fibromyalgia or as adjuntive therapy for adult partial onset seizures.[FDA Label]

Structured Indications
Pharmacodynamics

Pregabalin is a structural analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It has been reported that its action presents the function of modulating the release of many excitatory neurotransmitters such as glutamate, norepinephrine, subtance-P and calcitonin gene related peptide.This modulation can cause an inhibitory modulation of overexcited neurons allowing them to get back to a normal state, including te decrease on the hyper excitability caused by tissue damage.[6] The neurotransmitter modulation allows pregabalin to present antiallodynic, anxiolytic and anticonvulsant activity.[7]

Mechanism of action

Pregabalin binds presynaptically to the alpha2-delta subunit of the voltage-gated calcium channels in central nervous system tissues located in the brain and spinal cord.[6] The mechanism of action has not been fully elucidated but studies suggest that pregabalin produces a disruption of calcium channel traficking or a reduction of calcium currents. The inhibition of subunits of voltage-gated calcium channels reduces calcium release which in order inhibits the release of several neurotransmitters [FDA Label] Studies also suggest that the descending noradrenergic and serotonergic pathways originating from the brainstem may be involved with the mechanism of pregabalin. Interestingly, although pregabalin is a structural derivative of inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors.[8]

TargetActionsOrganism
AVoltage-dependent P/Q-type calcium channel subunit alpha-1A
inhibitor
Human
Absorption

Pregabalin has linear and dose-proportional absorption with a steady state achieved at 48-72 hours. Nowadays, there are two different formulations of pregabalin with different pharmacokinetic profiles, this is important due to the fact that the newest formulation has a propety of extended release. Pregabalin, in its both forms, presents a rapid absorption at fasting state. Pregabalin has a Cmax of 3.2mcg/ml, Tmax 0.7 hours and AUC 31.5mcg h/ml, while pregabalin CR (extended release) presents a Cmax 2.0mcg/ml, Tmax 8 hours and AUC 29.4mcg h/ml. Pregabalin is absorbed from the small intestine and proximal colon and its AUC values will depend on the type and quantity of meal calories ingested. [9]

Volume of distribution

Pregabalin does not bind to plasma proteins. The apparent volume of distribution after oral administration is 0.5 L/kg. Pregabalin passage across bloos brain barrier (BBB) is done through the system L. [10]

Protein binding

Pregabalin does not bind to plasma proteins.[FDA Label]

Metabolism

Pregabalin undergoes negligible metabolism in humans.[11]

Route of elimination

Pregabalin presents mainly a renal excretion, it has been reported that 90% of the administered dose is recovered unchanged in the urine. Secondly, it is possible to find N-methylated pregabalin in urine, and this metabolite can account for 0.9% of the dose. Pregabalin (S-enantiomer) did not undergo racemization to the R-enantiomer in pre-clinical studies. [11]

Half life

Mean elimination half-life is 6.3 hours in subjects with normal renal function.[12]

Clearance

Mean renal clearance is estimated to be 67 to 80.9 ml/min in young healthy subjects. Due to its lack of plasma protein binding, it is indicated the presence of renal tubular reabsorption.[FDA Label]

Toxicity

Most common adverse reactions presented in clinical trials are dizziness, somnolence, peripheral edema, nausea, blurred vision, dry mouth and weight gain.[FDA Label]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Pregabalin.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Pregabalin.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pregabalin is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Pregabalin is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Pregabalin.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alprazolam.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Pregabalin.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pregabalin.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Pregabalin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Pregabalin is combined with Aripiprazole.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Pregabalin.Approved
ArticaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Asenapine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Pregabalin is combined with Atosiban.Approved, Investigational
Atracurium besylatePregabalin may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Azaperone.Investigational, Vet Approved
AzelastinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Pregabalin is combined with Baclofen.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Pregabalin.Experimental
BarbexacloneThe metabolism of Pregabalin can be increased when combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Barbital.Illicit
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pregabalin.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Benzocaine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Pregabalin.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pregabalin is combined with Benzyl alcohol.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Pregabalin.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Pregabalin.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pregabalin is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved
BromazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the hypotensive activities of Pregabalin.Investigational
BunazosinBunazosin may increase the hypotensive activities of Pregabalin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Bupivacaine.Approved, Investigational
BuprenorphinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Pregabalin is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butabarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butamben.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Pregabalin.Approved
ButethalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butethal.Approved, Illicit
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Pregabalin.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butorphanol.Approved, Illicit, Vet Approved
Calcium AcetateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Pregabalin.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pregabalin.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Pregabalin is combined with Canertinib.Investigational
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Pregabalin.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pregabalin.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carbinoxamine.Approved
CarbomycinThe metabolism of Pregabalin can be decreased when combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carisoprodol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Pregabalin.Approved, Investigational
CaseinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Pregabalin.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Pregabalin.Approved
CetirizineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chloroprocaine.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Pregabalin.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorzoxazone.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Pregabalin.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pregabalin.Approved
CimetidineThe serum concentration of Pregabalin can be increased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Pregabalin is combined with Citalopram.Approved
ClarithromycinThe metabolism of Pregabalin can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Pregabalin is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Pregabalin.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clothiapine.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Pregabalin.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Codeine.Approved, Illicit
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Pregabalin.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cyclobenzaprine.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pregabalin.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dapiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Pregabalin.Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Pregabalin.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Diazepam.Approved, Illicit, Vet Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Pregabalin.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Pregabalin is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Doramectin.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Pregabalin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pregabalin is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ecgonine.Experimental, Illicit
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Pregabalin.Approved
EcopipamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Pregabalin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Pregabalin.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Eltanolone.Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pregabalin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pregabalin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Pregabalin is combined with Entacapone.Approved, Investigational
ErythromycinThe metabolism of Pregabalin can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Pregabalin is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Eszopiclone.Approved
EthanolPregabalin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Pregabalin.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Pregabalin can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Pregabalin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluticasone propionate.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Pregabalin.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pregabalin.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Pregabalin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Pregabalin is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pregabalin is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Pregabalin is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Glutethimide.Approved, Illicit
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Pregabalin.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Pregabalin.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Guanfacine.Approved, Investigational
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Pregabalin.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Pregabalin.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Heroin.Approved, Illicit, Investigational
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Pregabalin.Approved, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Hexobarbital.Approved
HydrocodonePregabalin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Iloperidone.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pregabalin.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Pregabalin is combined with Indiplon.Investigational
IndoraminIndoramin may increase the hypotensive activities of Pregabalin.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Pregabalin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Isoflurane.Approved, Vet Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Pregabalin.Approved, Investigational
JosamycinThe metabolism of Pregabalin can be decreased when combined with Josamycin.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Pregabalin.Approved, Investigational
KitasamycinThe metabolism of Pregabalin can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Pregabalin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pregabalin.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pregabalin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lormetazepam.Approved
LovastatinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Loxapine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lurasidone.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Magnesium salicylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Pregabalin is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Pregabalin is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Melperone.Approved, Investigational
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Pregabalin.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Meprobamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methohexital.Approved
MethotrimeprazinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methylphenobarbital.Approved
MetyrosinePregabalin may increase the sedative activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Pregabalin.Experimental
MianserinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Mianserin.Approved, Investigational
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Pregabalin.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Pregabalin.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Pregabalin is combined with Milnacipran.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Pregabalin.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Investigational
MirtazapinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumPregabalin may increase the neuromuscular blocking activities of Mivacurium.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pregabalin.Approved
MolindoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Molindone.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Pregabalin.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Morphine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Pregabalin.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Investigational
NafcillinThe metabolism of Pregabalin can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pregabalin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nalbuphine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Pregabalin.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nefazodone.Approved, Withdrawn
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Pregabalin.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Pregabalin.Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nitrazepam.Approved
NitroprussidePregabalin may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nitrous oxide.Approved, Vet Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Pregabalin.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nortriptyline.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Pregabalin.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Olanzapine.Approved, Investigational
OleandomycinThe metabolism of Pregabalin can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Olopatadine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Pregabalin.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Pregabalin.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Pregabalin is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Pregabalin can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Pregabalin is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxethazaine.Approved, Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Pregabalin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxymorphone.Approved, Investigational, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Pregabalin.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paliperidone.Approved
ParaldehydePregabalin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Penfluridol.Experimental
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Pregabalin.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved
PerazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pregabalin.Approved
PerospironeThe risk or severity of adverse effects can be increased when Pregabalin is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Pregabalin is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pregabalin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pimozide.Approved
PioglitazonePregabalin may increase the fluid retaining activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Piritramide.Investigational
PitavastatinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pitavastatin.Approved
PizotifenThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Pregabalin.Approved, Investigational, Vet Approved
PramipexolePregabalin may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pramocaine.Approved
PravastatinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Pregabalin.Approved
PrilocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Pregabalin is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Pregabalin is combined with PSD502.Investigational
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Pregabalin.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pregabalin.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Raclopride.Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Pregabalin.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pregabalin.Approved
RapacuroniumPregabalin may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Pregabalin is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Remoxipride.Approved, Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pregabalin.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pregabalin.Approved, Investigational
RifabutinThe serum concentration of Pregabalin can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Pregabalin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Pregabalin can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Pregabalin can be decreased when it is combined with Rifaximin.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Romifidine.Vet Approved
RopinirolePregabalin may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ropivacaine.Approved
RosiglitazonePregabalin may increase the fluid retaining activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Rosuvastatin.Approved
RotigotinePregabalin may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pregabalin.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Pregabalin.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pregabalin.Approved, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sepranolone.Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Pregabalin.Approved
SertindoleThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sevoflurane.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Pregabalin.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Pregabalin.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Pregabalin.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved
SolithromycinThe metabolism of Pregabalin can be decreased when combined with Solithromycin.Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Pregabalin.Approved
StiripentolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Pregabalin.Approved
SulpirideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sultopride.Experimental
SuvorexantPregabalin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Pregabalin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tasimelteon.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Pregabalin.Approved
TelithromycinThe metabolism of Pregabalin can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Temazepam.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Pregabalin.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Pregabalin.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Pregabalin.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Pregabalin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tetrodotoxin.Investigational
ThalidomidePregabalin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiothixene.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Pregabalin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tilidine.Experimental
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Pregabalin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tolcapone.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Pregabalin.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Pregabalin.Approved, Vet Approved
TopiramateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pregabalin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pregabalin.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Pregabalin.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Pregabalin.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triprolidine.Approved
TroglitazonePregabalin may increase the fluid retaining activities of Troglitazone.Investigational, Withdrawn
TylosinThe metabolism of Pregabalin can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UrapidilUrapidil may increase the hypotensive activities of Pregabalin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Pregabalin is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Pregabalin is combined with Vinyl ether.Experimental
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Pregabalin.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Pregabalin is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Pregabalin.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zolazepam.Vet Approved
ZolpidemPregabalin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol (may increase CNS effects).
  • When taken with food, Cmax decreases, while Tmax is prolonged. Despite these observations, the total absorption of pregabalin is not effected to a clinically relevant degree. Pregabalin can be taken with or without food.

References

Synthesis Reference

Mark Burk, "Asymmetric synthesis of pregabalin." U.S. Patent US20030212290, issued November 13, 2003.

US20030212290
General References
  1. Authors unspecified: Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist. 2005 Jul 28;70(144):43633-5. [PubMed:16050051]
  2. Su TZ, Feng MR, Weber ML: Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 2005 Jun;313(3):1406-15. Epub 2005 Mar 15. [PubMed:15769862]
  3. Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F, Cui M, Hoffman D, Donevan S: Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. Eur J Pharmacol. 2011 Sep 30;667(1-3):80-90. doi: 10.1016/j.ejphar.2011.05.054. Epub 2011 Jun 1. [PubMed:21651903]
  4. Bonnet U, Scherbaum N: How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017 Oct 5. pii: S0924-977X(17)30897-0. doi: 10.1016/j.euroneuro.2017.08.430. [PubMed:28988943]
  5. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L: Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol. 1997 Aug;121(8):1513-22. [PubMed:9283683]
  6. Rajappa GC, Vig S, Bevanaguddaiah Y, Anadaswamy TC: Efficacy of Pregabalin as Premedication for Post-Operative Analgesia in Vaginal Hysterectomy. Anesth Pain Med. 2016 May 14;6(3):e34591. doi: 10.5812/aapm.34591. eCollection 2016 Jun. [PubMed:27642577]
  7. Bender G, Florian JA Jr, Bramwell S, Field MJ, Tan KK, Marshall S, DeJongh J, Bies RR, Danhof M: Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. J Pharmacol Exp Ther. 2010 Aug;334(2):599-608. doi: 10.1124/jpet.110.166074. Epub 2010 May 5. [PubMed:20444880]
  8. Ben-Menachem E: Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 Suppl 6:13-8. [PubMed:15315511]
  9. Prompila N, Eiamart W, Jumroen Y, Sayankuldilok N, Chariyavilaskul P, Ketchat W, Wittayalertpanya S: Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects. Int J Clin Pharmacol Ther. 2017 Oct;55(10):811-817. doi: 10.5414/CP202954. [PubMed:28513426]
  10. Hong T, Han S, Lee J, Jeon S, Yim DS: Comparison of oral absorption models for pregabalin: usefulness of transit compartment model. Drug Des Devel Ther. 2016 Dec 7;10:3995-4003. eCollection 2016. [PubMed:27994441]
  11. Rodriguez J, Castaneda G, Munoz L: Direct determination of pregabalin in human urine by nonaqueous CE-TOF-MS. Electrophoresis. 2013 May;34(9-10):1429-36. doi: 10.1002/elps.201200564. Epub 2013 Apr 16. [PubMed:23463484]
  12. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN: Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003 Mar;43(3):277-83. [PubMed:12638396]
  13. Pfizer [Link]
External Links
Human Metabolome Database
HMDB14375
KEGG Drug
D02716
PubChem Compound
5486971
PubChem Substance
46504934
ChemSpider
4589156
BindingDB
50164279
ChEBI
64356
ChEMBL
CHEMBL1059
Therapeutic Targets Database
DAP001264
PharmGKB
PA164754814
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pregabalin
ATC Codes
N03AX16 — Pregabalin
AHFS Codes
  • 28:12.92 — Miscellaneous Anticonvulsants
FDA label
Download (3.46 MB)
MSDS
Download (106 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentNicotine Dependence1
0CompletedTreatmentPost-Operative Pain1
0RecruitingTreatmentCannabis-use Disorders1
1CompletedNot AvailableHealthy Volunteers10
1CompletedNot AvailableNerve Pain1
1CompletedBasic ScienceHealthy Volunteers8
1CompletedScreeningHealthy Volunteers1
1CompletedTreatmentDiabetic Neuropathies / Idiopathic Distal Sensory Polyneuropathy / Painful Small-Fiber Neuropathy / Postherpetic Neuralgia1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentPain, Acute1
1CompletedTreatmentPeripheral Neuropathy Pain1
1CompletedTreatmentPeripheral Nueropathy Pain1
1Not Yet RecruitingTreatmentHealthy Volunteers1
1Unknown StatusTreatmentRefractive Errors1
1, 2CompletedTreatmentEpilepsy, Localization Related1
1, 2CompletedTreatmentPrimary Total Knee Arthroplasty1
1, 2RecruitingTreatmentCoughing1
2CompletedNot AvailableFeeling Anxious1
2CompletedSupportive CareBrain and Central Nervous System Tumors / Seizures1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentCRP1
2CompletedTreatmentCancers / Pain1
2CompletedTreatmentDental Anxiety1
2CompletedTreatmentDiabetes Mellitus (DM) / Diabetic Neuropathies / Pain, Chronic1
2CompletedTreatmentDiabetic Neuropathic Pain1
2CompletedTreatmentDiabetic Neuropathies1
2CompletedTreatmentDiabetic Neuropathy, Painful2
2CompletedTreatmentDiabetic Neuropathy, Painful; Diabetic Neuropathies1
2CompletedTreatmentDiabetic Peripheral Neuropathic Pain2
2CompletedTreatmentDiabetic Peripheral Neuropathy (DPN)1
2CompletedTreatmentDiabetic Peripheral Neuropathy (DPN) / Pain1
2CompletedTreatmentElective Laparoscopic Cholecystectomy / Sevoflurane Anesthesia1
2CompletedTreatmentEpilepsy, Localization Related1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2CompletedTreatmentOveractive Bladder1
2CompletedTreatmentPain1
2CompletedTreatmentPain / Postherpetic Neuralgia1
2CompletedTreatmentPostherpetic Neuralgia1
2CompletedTreatmentRestless Legs Syndrome (RLS)1
2RecruitingTreatmentEarache1
2RecruitingTreatmentGulf War Illness1
2RecruitingTreatmentIdiopathic Small Fiber Neuropathy1
2TerminatedTreatmentFibromyalgia1
2TerminatedTreatmentHerpes Zoster / Postherpetic Neuralgia1
2TerminatedTreatmentOrofacial Pain / Pain, Neuropathic1
2TerminatedTreatmentPain, Chronic1
2TerminatedTreatmentPainful Diabetic Peripheral Neuropathy (PDPN)1
2TerminatedTreatmentPostherpetic Neuralgia1
2TerminatedTreatmentVulvar Vestibulitis / Vulvodynia1
2TerminatedTreatmentNeurocostal neuralgia1
2Unknown StatusTreatmentCancer, Breast / Drug-Related Side Effects and Adverse Reactions / Pain / Taxane1
2Unknown StatusTreatmentFibromyalgia / Pain, Chronic1
2WithdrawnTreatmentDiabetes Mellitus (DM) / Pain, Neuropathic1
2, 3Active Not RecruitingBasic ScienceFibromyalgia1
2, 3CompletedPreventionPostoperative pain1
2, 3CompletedTreatmentAcute Agitation / Dementias / Pain1
2, 3CompletedTreatmentDiabetes Mellitus (DM) / Peripheral Neuropathy1
2, 3CompletedTreatmentPancreatitis, Chronic1
2, 3RecruitingPreventionEye Dryness1
2, 3RecruitingPreventionPregabalin on Catheter Related Bladder Discomfort2
3Active Not RecruitingPreventionChronic Post-surgical Pain / Post-mastectomy Pain Syndrome1
3CompletedHealth Services ResearchHysterectomy1
3CompletedPreventionDelirium / Pain1
3CompletedPreventionPain / Pain, Neuropathic / Polyneuropathies1
3CompletedPreventionPost-Operative Pain1
3CompletedSupportive CareCancer, Breast / Menopausal Hot Flushes1
3CompletedSupportive CareIntervertebral Disc Herniation1
3CompletedTreatmentBreast Cancer Surgery / Post Operative Pain1
3CompletedTreatmentDiabetic Neuropathies1
3CompletedTreatmentDiabetic Neuropathies / Neurocostal neuralgia1
3CompletedTreatmentDiabetic Neuropathy, Painful7
3CompletedTreatmentDiabetic Peripheral Neuropathy (DPN)1
3CompletedTreatmentDiabetic Peripheral Neuropathy (DPN) / Nerve Pain1
3CompletedTreatmentDisseminated Sclerosis / Pain, Neuropathic1
3CompletedTreatmentEpilepsies1
3CompletedTreatmentEpilepsy, Complex Partial / Epilepsy, Localization Related1
3CompletedTreatmentEpilepsy, Localization Related2
3CompletedTreatmentEpilepsy, Localization Related / Sleep Deprivation1
3CompletedTreatmentEpilepsy, Localization Related / Partial onset seizure Epilepsy1
3CompletedTreatmentFeeling Anxious1
3CompletedTreatmentFibromyalgia13
3CompletedTreatmentFibromyalgia / Sleep disorders and disturbances1
3CompletedTreatmentGeneralized Anxiety Disorder (GAD)2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Peripheral Neuropathy2
3CompletedTreatmentIdiopathic Restless Legs Syndrome1
3CompletedTreatmentInguinal Hernias / Postoperative pain1
3CompletedTreatmentNeuroses, Anxiety1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentOsteoarthritis (OA) / Postoperative pain1
3CompletedTreatmentPain2
3CompletedTreatmentPain Associated With Fibromyalgia3
3CompletedTreatmentPain, Chronic1
3CompletedTreatmentPain, Neuropathic4
3CompletedTreatmentPainful Diabetic Peripheral Neuropathy (PDPN)1
3CompletedTreatmentNeurocostal neuralgia / Pain / Spinal Cord Diseases / Spinal Cord Injuries (SCI)1
3CompletedTreatmentPost-Herpetic Neuralgia (PHN)1
3CompletedTreatmentPostherpetic Neuralgia2
3CompletedTreatmentPostoperative pain3
3CompletedTreatmentRadicular syndrome1
3CompletedTreatmentRestless Legs Syndrome (RLS)1
3CompletedTreatmentSeizure Disorder, Partial4
3CompletedTreatmentSeizures1
3CompletedTreatmentNeurocostal neuralgia / Spinal Cord Injuries (SCI)1
3CompletedTreatmentNeurocostal neuralgia2
3CompletedTreatmentPartial onset seizure Epilepsy2
3Not Yet RecruitingPreventionHerpetic Neuralgia1
3Not Yet RecruitingPreventionPersistent Postoperative Pain1
3Not Yet RecruitingTreatmentAlcohol Use Disorder (AUD) / PTSD1
3RecruitingPreventionPhantom Pain1
3RecruitingPreventionPostoperative pain1
3RecruitingTreatmentEpilepsy, Partial Seizures / Epilepsy, Primary Generalized Tonic-Clonic Seizures1
3RecruitingTreatmentFibromyalgia1
3RecruitingTreatmentLiver Cirrhosis / Muscle Cramps1
3RecruitingTreatmentPain of Mononeuropathy1
3RecruitingTreatmentPain, Neuropathic1
3RecruitingTreatmentPeripheral Neuropathic Pain1
3RecruitingTreatmentPostherpetic Neuralgia1
3TerminatedPreventionPain / Spinal Cord Trauma1
3TerminatedSupportive CarePerioperative Pain1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentEpilepsies1
3TerminatedTreatmentEpilepsy, Localization Related1
3TerminatedTreatmentFusion of Spine (Disease)1
3TerminatedTreatmentInfection, Human Immunodeficiency Virus I / Pain, Neuropathic1
3TerminatedTreatmentNeuropathy1
3Unknown StatusPreventionInguinal Hernias / Postoperative pain1
3Unknown StatusTreatmentCancers / Neurocostal neuralgia1
3Unknown StatusTreatmentChronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)1
3Unknown StatusTreatmentDiabetic Neuropathies1
3Unknown StatusTreatmentPostoperative pain1
3WithdrawnPreventionPain, Chronic1
3WithdrawnTreatmentMigraine Disorders1
3WithdrawnTreatmentRestless Legs Syndrome (RLS)1
4Active Not RecruitingTreatmentAlcoholism1
4Active Not RecruitingTreatmentCryptogenic Sensory Polyneuropathy1
4Active Not RecruitingTreatmentPain, Acute1
4Active Not RecruitingTreatmentPost Operative Pain1
4CompletedNot AvailableHealthy Lactating Women1
4CompletedNot AvailableHealthy Volunteers2
4CompletedNot AvailableIrritable Bowel Syndrome (IBS)1
4CompletedNot AvailablePain, Neuropathic2
4CompletedNot AvailablePostoperative pain1
4CompletedDiagnosticAnxiety Disorders1
4CompletedOtherHealthy Volunteers1
4CompletedTreatmentAnxiety-comorbidity to Schizophrenia / Schizophrenic Disorders1
4CompletedTreatmentCentral Neuropathic Pain1
4CompletedTreatmentCervical Spondylosis / Cervical Spondylotic Myelopathy / Cervical Spondylotic Radiculopathy1
4CompletedTreatmentChemotherapy Induced Neuropathic Pain / Diabetic Peripheral Neuropathic Pain (DPN) / HIV-related Neuropathic Pain (HIV) / Postherpetic Neuralgia ( PHN )1
4CompletedTreatmentComplex Partial Seizure Disorder / Epilepsies / Epilepsy, Localization Related / Partial Seizure Disorder1
4CompletedTreatmentDiabetic Neuropathies1
4CompletedTreatmentDiabetic Neuropathy, Painful3
4CompletedTreatmentDiabetic Peripheral Neuropathic Pain2
4CompletedTreatmentDiabetic Peripheral Neuropathy (DPN)1
4CompletedTreatmentDisk Prolapse / Intervertebral Disk Displacement1
4CompletedTreatmentEpilepsies1
4CompletedTreatmentEpilepsy, Localization Related1
4CompletedTreatmentFailed Back Surgery Syndrome / Intervertebral Disc Herniation / Neuropathy; Radicular, Lumbar, Lumbosacral / Spinal Stenosis1
4CompletedTreatmentFibromyalgia4
4CompletedTreatmentGeneralized Anxiety Disorder (GAD)1
4CompletedTreatmentLaparoscopic Cholecystectomy / Postoperative pain1
4CompletedTreatmentLiving Donors1
4CompletedTreatmentLumbar Spinal Fusions1
4CompletedTreatmentNeurogenic Intermittent Claudication / Spinal Stenosis of Lumbar Region1
4CompletedTreatmentNeurologic Claudication in Patients With Lumbar Spinal Stenosis1
4CompletedTreatmentNon-diabetic Painful Peripheral Polyneuropathy / Peripheral Nerve Injury (PNI) / Postherpetic Neuralgia ( PHN )1
4CompletedTreatmentOpioids Use / Postoperative pain1
4CompletedTreatmentPain1
4CompletedTreatmentPain, Chronic1
4CompletedTreatmentPainful Diabetic Neuropathy and Post Herpetic Neuralgia1
4CompletedTreatmentPain / Postoperative1
4CompletedTreatmentPost-Herpetic Neuralgia (PHN)1
4CompletedTreatmentPost-Operative Pain1
4CompletedTreatmentPost-thoracotomy Pain1
4CompletedTreatmentPostherpetic Neuralgia ( PHN )1
4CompletedTreatmentPostoperative Pain Management1
4CompletedTreatmentPostoperative Pain Management / Total Knee Arthroplasty (TKA)1
4CompletedTreatmentPostoperative pain3
4CompletedTreatmentSeizures1
4CompletedTreatmentNeurocostal neuralgia / Spinal Cord Injuries (SCI)1
4CompletedTreatmentAdjunct to general anesthesia therapy / Surgery, Laparoscopic1
4CompletedTreatmentTremor, Essential2
4CompletedTreatmentNeurocostal neuralgia1
4Not Yet RecruitingTreatmentPain, Neuropathic1
4RecruitingSupportive CareScoliosis / Spondylolisthesis1
4RecruitingTreatmentArterial Occlusive Diseases / Critical Limb Ischemia (CLI) / Pain / Transient ischemia attacks1
4RecruitingTreatmentEpilepsy, Localization Related1
4RecruitingTreatmentHepatocellular Cancer1
4RecruitingTreatmentLumbar Disc Disease / Lumbar Radiculopathy / Prolapsed Lumbar Disc1
4RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
4RecruitingTreatmentOpiate withdrawal symptoms1
4TerminatedBasic ScienceSubstance-Related Disorders1
4TerminatedTreatmentAbdominal Pain (AP) / Surgical Adhesions1
4TerminatedTreatmentBone Neoplasms / Cancers / Pain, Intractable1
4TerminatedTreatmentChemotherapy-induced Peripheral Neuropathy (CIPN)1
4TerminatedTreatmentChronic Low Back Pain With a Neuropathic Component1
4TerminatedTreatmentEpilepsies / Feeling Anxious1
4TerminatedTreatmentEpilepsy, Complex Partial1
4TerminatedTreatmentMalignant Neoplasm of Pancreas / Visceral Pain1
4TerminatedTreatmentPostherpetic Neuralgia1
4TerminatedTreatmentPostoperative pain1
4TerminatedTreatmentUterine Artery Embolization / Uterine Leiomyomas1
4TerminatedTreatmentPartial onset seizure Epilepsy1
4Unknown StatusBasic ScienceDiabetes Mellitus (DM) / Painful Distal Symmetric Sensorimotor Polyneuropathy1
4Unknown StatusPreventionChronic Illnesses / Hyperalgesia / Pain / Pain, Neuropathic1
4Unknown StatusTreatmentFeeling Anxious1
4Unknown StatusTreatmentPain, Neuropathic / Spinal Cord Injuries (SCI)1
4Unknown StatusTreatmentPain, Neuropathic / Tactile Hyperalgesia1
4Unknown StatusTreatmentPolyneuropathies1
4Unknown StatusTreatmentUremic Pruritus2
4WithdrawnDiagnosticLow Back Pain (LBP) / Neurocostal neuralgia1
4WithdrawnTreatmentChronic Pain, Postoperative / Headaches1
4WithdrawnTreatmentDiabetic Polyneuropathy / Postherpetic Neuralgia1
4WithdrawnTreatmentFibromyalgia1
4WithdrawnTreatmentRestless Legs Syndrome (RLS)1
Not AvailableActive Not RecruitingPreventionPain, Cancer / Pain, Neuropathic / Persistent Post-surgical Pain1
Not AvailableActive Not RecruitingSupportive CarePain / Peripheral Neuropathy1
Not AvailableCompletedNot AvailableBlock1
Not AvailableCompletedNot AvailableEpilepsies1
Not AvailableCompletedNot AvailableEpilepsies / Fibromyalgia / Pain, Neuropathic / Post-market Surveillance1
Not AvailableCompletedNot AvailableEpilepsies / Neurocostal neuralgia1
Not AvailableCompletedNot AvailablePain Associated With Fibromyalgia1
Not AvailableCompletedNot AvailablePain, Neuropathic2
Not AvailableCompletedNot AvailableNeurocostal neuralgia1
Not AvailableCompletedPreventionPain2
Not AvailableCompletedPreventionPain, Neuropathic1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedSupportive CarePain / Peripheral Neuropathy1
Not AvailableCompletedSupportive CarePostoperative pain1
Not AvailableCompletedTreatmentHepatocellular,Carcinoma / Postoperative pain1
Not AvailableCompletedTreatmentPain2
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableNot Yet RecruitingPreventionAnterior Cruciate Ligament (ACL) Reconstruction1
Not AvailableNot Yet RecruitingTreatmentFibromyalgia / Hyperbaric Oxygen1
Not AvailableNot Yet RecruitingTreatmentPeripheral Arterial Disease (PAD)1
Not AvailableRecruitingNot AvailablePain, Neuropathic / Postoperative pain1
Not AvailableRecruitingOtherNeuropathy / Pain1
Not AvailableRecruitingSupportive CarePostoperative pain1
Not AvailableRecruitingSupportive CareSpine Surgery1
Not AvailableRecruitingTreatmentOropharyngeal Cancers / Squamous Cell Carcinoma to the Head and Neck1
Not AvailableSuspendedTreatmentSmall-Fiber Neuropathy1
Not AvailableTerminatedNot AvailableSpinal Cord Injuries (SCI)1
Not AvailableTerminatedTreatmentChronic Pain, Postoperative1
Not AvailableTerminatedTreatmentCocaine Abuse / Cocaine-Related Disorders1
Not AvailableTerminatedTreatmentComplex Regional Pain Syndromes (CRPS)1
Not AvailableTerminatedTreatmentPostoperative pain1
Not AvailableUnknown StatusSupportive CareNasal Septum Deviation1
Not AvailableUnknown StatusSupportive CarePain1
Not AvailableUnknown StatusSupportive CarePostoperative pain1
Not AvailableUnknown StatusTreatmentFibromyalgia1
Not AvailableUnknown StatusTreatmentMultimodal Analgesia / Postoperative Pain Control1
Not AvailableUnknown StatusTreatmentTo Assess the Beneficial Preemptive and Preventive Effects of PGL on the Immediate and Late (1- and 3 Months) Postoperative Analgesia Requirements1
Not AvailableWithdrawnPreventionPain1

Pharmacoeconomics

Manufacturers
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral100 mg
CapsuleOral150 mg/1
CapsuleOral150 mg
CapsuleOral200 mg
CapsuleOral200 mg/1
CapsuleOral225 mg
CapsuleOral225 mg/1
CapsuleOral25 mg/1
CapsuleOral25 mg
CapsuleOral300 mg
CapsuleOral300 mg/1
CapsuleOral50 mg
CapsuleOral50 mg/1
CapsuleOral75 mg/1
CapsuleOral75 mg
SolutionOral20 mg/mL
Tablet, film coated, extended releaseOral165 mg/1
Prices
Unit descriptionCostUnit
Lyrica 100 mg capsule2.88USD capsule
Lyrica 150 mg capsule2.88USD capsule
Lyrica 50 mg capsule2.88USD capsule
Lyrica 75 mg capsule2.88USD capsule
Lyrica 200 mg capsule2.75USD capsule
Lyrica 225 mg capsule2.75USD capsule
Lyrica 25 mg capsule2.75USD capsule
Lyrica 300 mg capsule2.75USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5563175No1993-10-082013-10-08Us
CA2327285No2005-06-142019-05-10Canada
CA2297163No2001-11-202018-08-18Canada
US6001876No1998-12-302018-12-30Us
USRE41920No1998-12-302018-12-30Us
US6197819No1998-12-302018-12-30Us
US9144559No2006-11-022026-11-02Us
US8945620No2006-11-022026-11-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)186-188ºCNot Available
boiling point (°C)274ºC at 760 mm HgNot Available
water solubilityFreely soluble FDA label
logP-1.35FDA label
pKa4.2 and 10.6 FDA label
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP-1.4ALOGPS
logP-1.3ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)4.8ChemAxon
pKa (Strongest Basic)10.23ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity43.68 m3·mol-1ChemAxon
Polarizability18.08 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9727
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6531
P-glycoprotein substrateNon-substrate0.683
P-glycoprotein inhibitor INon-inhibitor0.965
P-glycoprotein inhibitor IINon-inhibitor0.9424
Renal organic cation transporterNon-inhibitor0.9245
CYP450 2C9 substrateNon-substrate0.8758
CYP450 2D6 substrateNon-substrate0.7926
CYP450 3A4 substrateNon-substrate0.6914
CYP450 1A2 substrateNon-inhibitor0.9385
CYP450 2C9 inhibitorNon-inhibitor0.9425
CYP450 2D6 inhibitorNon-inhibitor0.9539
CYP450 2C19 inhibitorNon-inhibitor0.9629
CYP450 3A4 inhibitorNon-inhibitor0.9352
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9784
Ames testNon AMES toxic0.938
CarcinogenicityNon-carcinogens0.5678
BiodegradationReady biodegradable0.8201
Rat acute toxicity1.7046 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9868
hERG inhibition (predictor II)Non-inhibitor0.8909
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-555454e7e8e11dab591d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-1a52554257d7f4b1c62e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-d48cd6eeef012787cc04
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-4b11df5208caa2e97dd2
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-605dc241ffd3a07a9220
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ox-0900000000-fb081cde39dde2ce89f8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-3d95bb5278c7866658a0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-96cebf4a3610cbf02059
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-8900000000-385584fca9e88b90a95b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9800000000-a1c6718b087b06101b8d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9200000000-5f291c943a1d1ae214ad
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9100000000-5283d02d98611a8c2c38
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9000000000-8797f8d2776fcdb4b6d5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9000000000-a9ddfcf2032ffc9f53ad

Taxonomy

Description
This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Gamma amino acids and derivatives
Alternative Parents
Medium-chain fatty acids / Branched fatty acids / Amino fatty acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives
show 1 more
Substituents
Gamma amino acid or derivatives / Medium-chain fatty acid / Amino fatty acid / Branched fatty acid / Fatty acyl / Fatty acid / Amino acid / Carboxylic acid / Monocarboxylic acid or derivatives / Amine
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
gamma-amino acid (CHEBI:64356)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1A
Uniprot ID
O00555
Uniprot Name
Voltage-dependent P/Q-type calcium channel subunit alpha-1A
Molecular Weight
282362.39 Da
References
  1. Gazulla J, Tintore M: The P/Q-type voltage-dependent calcium channel: a therapeutic target in spinocerebellar ataxia type 6. Acta Neurol Scand. 2007 May;115(5):356-63. [PubMed:17489948]
  2. Gazulla J, Tintore MA: The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses. 2007;68(1):131-6. Epub 2006 Aug 8. [PubMed:16899342]
  3. Jacquy J, Lossignol D, Sternon J: [Pregabalin (Lyrica) and neuropathic pain syndromes]. Rev Med Brux. 2006 Sep-Oct;27(5):445-50. [PubMed:17144644]
  4. Taylor CP, Angelotti T, Fauman E: Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007 Feb;73(2):137-50. Epub 2006 Nov 28. [PubMed:17126531]
  5. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T, Williams D: Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17537-42. Epub 2006 Nov 6. [PubMed:17088553]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Sodium:dicarboxylate symporter activity
Specific Function
Transports L-glutamate, L- and D-aspartate and L-cystein (PubMed:21123949). Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic c...
Gene Name
SLC1A1
Uniprot ID
P43005
Uniprot Name
Excitatory amino acid transporter 3
Molecular Weight
57099.835 Da
References
  1. Ryu JH, Lee PB, Kim JH, Do SH, Kim CS: Effects of pregabalin on the activity of glutamate transporter type 3. Br J Anaesth. 2012 Aug;109(2):234-9. doi: 10.1093/bja/aes120. Epub 2012 Apr 16. [PubMed:22511482]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18